New results published on Pharmexa's PADRE® epitope in Alzheimer's vaccine
The prototype vaccine, a combination of a fragment of the Abeta peptide and Pharmexa's PADRE® epitope, gave rise to high anti-Abeta antibody titers in vaccinated mice. No unwanted cellular immune responses were detected, and there were no signs of side effects in the brains of the animals. These independent data therefore confirm Pharmexa's hypotheses that a safe and effective Alzheimer's vaccine may be developed using dominant helper cell epitopes such as PADRE® that will alleviate the side effects observed with earlier Abeta vaccines.
The Abeta peptide is believed to have a central role in the onset and progression of Alzheimer's disease. Pharmexa, in collaboration with H. Lundbeck, as well as other pharmaceutical and biotech companies, has therefore been targeting the Abeta peptide for a therapeutic Alzheimer's vaccine.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.